ArticleInfectious diseases and therapy2021

Safety Evaluation of Recombinant Fusion Protein RP22 as a Skin Test Reagent for Tuberculosis Diagnosis: A Phase I Clinical Trial.

Lu Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.